Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | VITA LIFE SCIENCES LIMITED: Notice of General Meeting/Proxy Form | - | ASX | ||
Fr | VITA LIFE SCIENCES LIMITED: Vested Plan Shares | - | ASX | ||
Mi | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
Mi | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
12.04. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
11.04. | VITA LIFE SCIENCES LIMITED: Capital Update-Vested Plan Shares | - | ASX | ||
11.04. | VITA LIFE SCIENCES LIMITED: Cleansing Statement | - | ASX | ||
11.04. | VITA LIFE SCIENCES LIMITED: Application for quotation of securities - VLS | - | ASX | ||
10.04. | VITA LIFE SCIENCES LIMITED: Change of AGM Date | - | ASX | ||
09.04. | VITA LIFE SCIENCES LIMITED: Daily share buy-back notice - Appendix 3E | - | ASX | ||
26.03. | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
21.03. | VITA LIFE SCIENCES LIMITED: Application for quotation of securities - VLS | 1 | ASX | ||
21.03. | VITA LIFE SCIENCES LIMITED: Application for quotation of securities - VLS | 1 | ASX | ||
18.03. | VITA LIFE SCIENCES LIMITED: Annual Report to shareholders | - | ASX | ||
18.03. | VITA LIFE SCIENCES LIMITED: Appendix 4G Corporate Governance Statement | - | ASX | ||
14.03. | VITA LIFE SCIENCES LIMITED: AGM Date and Closing Date for Directors' Nomination | - | ASX | ||
12.03. | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | 1 | ASX | ||
26.02. | Australia's Vita Life Sciences hits 1-1/2-year high on upbeat FY results | 1 | Reuters | ||
26.02. | VITA LIFE SCIENCES LIMITED: Dividend/Distribution - VLS | 1 | ASX | ||
26.02. | VITA LIFE SCIENCES LIMITED: Full Year Results Presentation | 1 | ASX |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
GREEN THUMB INDUSTRIES | 11,670 | -3,79 % | Green Thumb Industries: Aktie muss nachsetzen | Anzeige / WerbungLetztendlich blieben aber positive Impulse auf den Aktienkurs aus. Dabei wären diese dringend notwendig.Green Thumb Industries veröffentlichte am gestrigen Mittwoch (28. Februar) die... ► Artikel lesen | |
INDIVA | 0,021 | 0,00 % | Indiva Ltd: Indiva to release 2023 results April 25 | ||
ALNYLAM PHARMACEUTICALS | 137,45 | +0,84 % | How Is The Market Feeling About Alnylam Pharmaceuticals? | ||
NEKTAR THERAPEUTICS | 1,138 | -6,49 % | NEKTAR THERAPEUTICS - 8-K, Current Report | ||
CASSAVA SCIENCES | 18,470 | -7,21 % | CASSAVA SCIENCES INC - 8-K, Current Report | ||
ADASTRA | 0,138 | -4,83 % | Adastra Holdings Ltd.: Adastra Holdings Announces Lachlan McLeod as Interim CEO | LANGLEY, BC / ACCESSWIRE / April 15, 2024/ Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis processor and producer of two top Canadian concentrates brands... ► Artikel lesen | |
ACADIA PHARMACEUTICALS | 15,825 | -1,22 % | Aktien New York: Indizes bauen Gewinne aus - Inflationsdaten im Fokus | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben nach einem trägen Wochenstart am Dienstag zugelegt. Allerdings reagierten die Aktienkurse erst mit einiger Verzögerung positiv auf US-Inflationsdaten... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 1,460 | +2,82 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update | Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified Biomarkers... ► Artikel lesen | |
NUMINUS WELLNESS | 0,055 | -11,04 % | Numinus Wellness Inc.: Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003 | VANCOUVER, BC, April 17, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral... ► Artikel lesen | |
CATALYST PHARMACEUTICALS | 14,695 | +1,94 % | Santhera Pharmaceuticals Holding AG: Santhera's Partner Catalyst Pharmaceuticals lanciert AGAMREE® (Vamorolon) in den Vereinigten Staaten | AGAMREE® ist von der U.S. FDA zugelassen und jetzt in den USA für die Behandlung von Duchenne-Muskeldystrophie (DMD) bei Patienten ab 2 Jahren erhältlichDies folgt auf die erste kommerzielle Einführung... ► Artikel lesen | |
MOLECULE HOLDINGS | 0,001 | 0,00 % | XFRA ERV2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMOLECULE HOLDINGS... ► Artikel lesen | |
SOLIGENIX | 0,431 | +2,77 % | SOLIGENIX, INC.: FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection | Provides MarVax Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval
PRINCETON, N.J., April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company)... ► Artikel lesen | |
OCUPHIRE PHARMA | 1,688 | +7,24 % | Ocuphire Pharma, Inc. - 8-K, Current Report | ||
ZELIRA THERAPEUTICS | 0,412 | 0,00 % | ZELIRA THERAPEUTICS LIMITED: Zelira receives $919,000 R&D Tax Incentive Scheme Refund | ||
ANI PHARMACEUTICALS | 60,50 | -0,82 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET |